London, UK – In a significant stride for cancer research, an international collaborative team of scientists from the Francis Crick Institute, UCL, Gustave Roussy, and Memorial Sloan Kettering Cancer Center (MSK) has unveiled a critical link between the natural process of ageing and the aggressive progression of cancer. Their pioneering work reveals that the expansion of mutant blood cells, a common phenomenon in older individuals, infiltrates cancerous tumours, a condition they term Tumour Infiltrating Clonal Haematopoiesis (TI-CH), and is strongly associated with a significantly worse prognosis for patients across various cancer types.
Published today in the prestigious New England Journal of Medicine, this comprehensive study sheds new light on the intricate interplay between age-related genetic changes and the evolution of solid cancers. The findings not only offer a novel prognostic marker but also open promising avenues for developing preventative and targeted therapies for a growing global population grappling with age-related diseases like cancer.
Main Facts: The Silent Threat of Ageing Blood Cells
The core of this groundbreaking discovery lies in understanding Clonal Haematopoiesis of Indeterminate Potential (CHIP). CHIP is a condition where blood stem cells, over time and influenced by both natural ageing and environmental factors, accumulate specific genetic mutations. While often asymptomatic and not directly cancerous in itself, CHIP has previously been linked to an increased risk of age-related disorders, notably cardiovascular disease. However, its direct impact on solid cancer evolution remained largely unexplored until now.
The researchers found that these mutant blood cells are not merely circulating in the bloodstream; in a significant proportion of cancer patients, they actively infiltrate the tumour microenvironment. This infiltration, dubbed Tumour Infiltrating Clonal Haematopoiesis (TI-CH), was identified as the crucial factor driving worse outcomes, including higher rates of cancer relapse and increased mortality, irrespective of the patient’s age or the stage at which their cancer was initially diagnosed.
Key findings include:
- CHIP mutations were detected in the blood of cancer patients and initially correlated with shorter survival.
- Crucially, these CHIP mutations were found within lung tumours in 42% of patients with CHIP, a phenomenon termed TI-CH.
- TI-CH, rather than CHIP alone, was directly associated with a greater risk of cancer relapse and death.
- The study identified a specific gene mutation, TET2, as a key player. When TET2 is mutated, it leads to an expansion of myeloid cells, a type of immune cell known to promote tumour growth and spread.
- Experimental models demonstrated that TET2 mutant myeloid cells actively remodel the tumour microenvironment and accelerate tumour growth.
- Validation across a massive dataset of over 49,000 patients with various cancer types confirmed TI-CH as an independent predictor of shorter survival, particularly prevalent in aggressive cancers like lung, head and neck, and pancreatic cancers.
This interdisciplinary research, spearheaded by Oriol Pich, Elsa Bernard, and Maria Zagorulya, underscores a profound biological interface between normal ageing processes and the pathology of cancer, providing critical insights into how the body’s own age-related changes can inadvertently contribute to the aggressiveness of a disease.
Chronology of Discovery: Unraveling an Intricate Link
The Unseen Link: Ageing, Blood, and Cancer
For decades, scientists have grappled with the complex relationship between ageing and the increased incidence and aggressiveness of diseases like cancer. As individuals age, their cells accumulate genetic changes, some of which are benign, while others can lay the groundwork for pathology. Clonal haematopoiesis (CH), and specifically CHIP, represents one such age-related phenomenon. It’s estimated that CHIP is present in over 10% of individuals over the age of 65, making it a widespread, yet often unnoticed, biological change. Prior research had established CHIP’s connection to inflammatory conditions and cardiovascular disease, painting a picture of these mutated blood cells as potential instigators of systemic issues. However, their direct role in the solid tumour landscape remained a scientific blind spot. The question loomed: could these age-related blood cell mutations influence the development and progression of solid cancers, distinct from their known roles in blood cancers or cardiovascular health? This profound question served as the impetus for the ambitious undertaking that led to the current findings.
Initiating the Investigation: The TRACERx and PEACE Studies
To thoroughly investigate this intricate connection, the research team leveraged the unparalleled resources of two major Cancer Research UK-funded initiatives: the TRACERx (TRAcking Cancer Evolution through therapy (Rx)) study and the PEACE (Postmortem ExamiAtion of Cancer Evolution) study. TRACERx is a groundbreaking longitudinal study tracking the evolutionary trajectories of lung cancers from diagnosis through treatment and recurrence, providing an unprecedented wealth of clinical and genomic data from hundreds of patients. The PEACE study complements TRACERx by performing rapid post-mortem analyses of patients who have died from cancer, allowing researchers to examine metastatic sites – the primary cause of cancer mortality – in exquisite detail.
The initial phase of the investigation involved meticulously examining blood samples from over 400 lung cancer patients enrolled in these studies. The goal was to identify which patients carried CHIP mutations in their blood, acting as a baseline assessment of their age-related haematopoietic landscape. This crucial step allowed the researchers to establish the prevalence of CHIP within a cohort of cancer patients and set the stage for correlating these genetic markers with clinical outcomes.
The Critical Observation: CHIP’s Shadow on Survival
Upon identifying patients with CHIP mutations, the research team embarked on a critical correlational analysis. They matched the presence of these mutations with extensive clinical data, including patient survival rates, cancer stage at diagnosis, and age. The results were striking: patients with CHIP mutations in their blood were found to live for a significantly shorter period. What made this observation particularly compelling was that this association held true regardless of the patient’s age or the stage at which their cancer had been diagnosed. This initial finding was a powerful indicator that CHIP was not merely a benign bystander but an independent factor influencing cancer prognosis, signaling that something more profound was at play than just chronological age or tumour burden alone. It suggested that the intrinsic genetic makeup of a patient’s blood system, shaped by years of ageing, could directly dictate the severity and outcome of their cancer.
Unveiling TI-CH: The Infiltrating Threat
The discovery of CHIP’s prognostic significance spurred the team to delve deeper. They hypothesized that if CHIP was impacting cancer outcomes, it might be doing so by directly interacting with the tumour itself. This led to the pivotal investigation into whether the specific CHIP mutations found in patients’ blood were also present within their lung tumours, potentially due to the infiltration of these mutant blood cells. This meticulous analysis revealed a groundbreaking truth: in a staggering 42% of patients with CHIP, these age-related mutations were indeed found within the tumour tissue. This phenomenon was given a specific designation: Tumour Infiltrating Clonal Haematopoiesis (TI-CH).
The subsequent and even more critical finding was the distinction between CHIP and TI-CH. It was TI-CH – the actual presence of these mutant blood cells within the tumour microenvironment – and not merely the presence of CHIP in the blood, that was robustly associated with the greater risk of cancer relapse and, ultimately, cancer-related death. This finding transformed the understanding from a correlation to a more direct, mechanistic link. Further bolstering this conclusion, samples from the PEACE study, which examined metastatic tumours – the main cause of cancer death – often contained these same TI-CH mutations, unequivocally confirming that these infiltrating mutant cells were present at the most aggressive and lethal sites of cancer spread. This confirmed that the age-related blood mutations were not just biomarkers but active participants in the deadly progression of the disease.
Supporting Data and Mechanisms: Dissecting the Biological Blueprint
Delving Deeper: The Tumour Microenvironment
To fully comprehend the impact of TI-CH, the researchers turned their attention to the intricate ecosystem surrounding the cancer cells, known as the tumour microenvironment (TME). The TME is a complex milieu comprising various cell types, including immune cells, fibroblasts, blood vessels, and extracellular matrix, all of which interact dynamically with cancer cells. It’s now widely recognized that the TME plays a pivotal role in tumour initiation, growth, metastasis, and response to therapy. The composition and activity of cells within the TME can either suppress or promote cancer progression. Understanding which cells infiltrate the tumour and how they behave is therefore paramount to unraveling the mechanisms of cancer aggressiveness. The presence of TI-CH suggested that age-related changes in blood cell populations were fundamentally altering this critical environment.
Myeloid Cells: Double-Edged Swords
Upon analyzing the cellular composition of lung tumours in patients with TI-CH, the scientists made another crucial discovery: these tumours exhibited a significant expansion of myeloid cells. Myeloid cells are a broad category of immune cells that include macrophages, neutrophils, and dendritic cells, among others. While some immune cells, such as cytotoxic T-cells, are renowned for their ability to recognize and destroy cancer cells, myeloid cells often present a more complex, "double-edged sword" role in the context of cancer. In healthy tissues, myeloid cells are essential for immune surveillance, wound healing, and regulating inflammation. However, within the TME, many myeloid cell subsets, particularly tumour-associated macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs), become reprogrammed. They can suppress anti-tumour immune responses, promote angiogenesis (new blood vessel formation critical for tumour growth), facilitate cancer cell invasion and metastasis, and regulate chronic inflammation that fuels tumour progression. The expansion of these pro-tumourigenic myeloid cells in TI-CH patients offered a compelling mechanistic explanation for the observed worse outcomes.
The Role of TET2: A Genetic Culprit
The investigation then pinpointed a specific genetic mutation as a key driver of this myeloid cell expansion and infiltration: mutations in the TET2 gene. TET2 is a critical epigenetic regulator involved in DNA demethylation, a process vital for normal blood cell production and differentiation. When the TET2 gene is mutated, it disrupts this delicate balance, leading to the skewed development and expansion of certain blood cell lineages. The researchers discovered that among thousands of individuals studied, TET2 mutant blood cells were significantly more likely to infiltrate solid tumours. Further high-resolution single-cell analysis of hundreds of cells from the tumours of two TI-CH patients confirmed that the TET2 mutations were predominantly present in myeloid cells, and not in other immune cell types, cementing its role in shaping the pro-tumourigenic myeloid compartment within the TME. This provided a specific genetic pathway explaining why certain CHIP clones become problematic infiltrators.
Experimental Validation: Organoids in Action
To move beyond correlation and establish a causal link, the research team engaged in a crucial collaboration with blood cancer and CHIP experts at a Crick lab led by Dominique Bonnet. Together, they designed elegant experimental models using organoids – three-dimensional mini-tumours grown in a laboratory setting that closely mimic the structure and function of actual human tumours. They co-cultured these lung tumour organoids with TET2 mutant myeloid cells. The results were unequivocal: the TET2 mutant myeloid cells actively remodeled the tumour microenvironment, creating conditions more favorable for cancer growth, and significantly accelerated the growth of the tumour organoids. This powerful experimental evidence provided direct functional proof that TET2 mutated myeloid cells are not just markers of aggressive cancer but actively contribute to its progression, offering a compelling mechanistic explanation for the clinical observations.
Beyond Lung Cancer: A Widespread Phenomenon
Recognizing the potential broader implications of their findings, the team embarked on a large-scale validation study in collaboration with researchers at Memorial Sloan Kettering Cancer Center in the US. They utilized an extensive dataset encompassing over 49,000 patients with a wide array of different cancer types. This massive dataset allowed for a robust assessment of TI-CH’s prevalence and prognostic significance across the cancer spectrum. The findings were consistent: the presence of TI-CH emerged as an independent predictor of shorter survival across various cancer types. While the prevalence of CHIP and TI-CH varied between different cancers, it was notably more common in cancers known for their aggressive nature and resistance to treatment, such as lung cancer (the initial focus), head and neck cancer, and pancreatic cancer. This widespread validation underscores that TI-CH is not a lung cancer-specific phenomenon but rather a general mechanism by which age-related blood cell mutations can contribute to the aggressiveness of diverse solid tumours, marking it as a critical factor in understanding and combating some of the most challenging forms of cancer.
Official Responses and Expert Commentary: Charting the Future of Cancer Care
Voices from the Frontline of Research
The researchers behind this landmark study articulated the profound implications of their findings. Oriol Pich, a Postdoctoral Project Research Scientist in the Crick’s Cancer Evolution and Genome Instability Laboratory and a lead author of the study, emphasized the direct impact on patients: "Our results show that blood cells carrying age-related mutations can infiltrate tumours and impact cancer evolution, leading to worse outcomes for patients. This is important because CHIP is a natural phenomenon of ageing that is common in patients with cancer." Pich’s statement highlights the pervasive nature of CHIP and its newfound role as a critical, yet previously overlooked, factor in cancer prognosis, underscoring the urgency for clinical consideration.
Professor Charlie Swanton, Deputy Clinical Director at the Crick, Chief Clinician at Cancer Research UK, and Chief Investigator for the TRACERx study, provided broader context, connecting the discovery to the larger narrative of ageing and disease. "This is the first time that we’ve been able to see at scale, the interaction of two different types of ‘clonal proliferations’, age-related CHIP and cancer, providing insight into how ageing might impact cancer risk," Professor Swanton remarked. His commentary illuminates the study’s significance in bridging two distinct biological processes – normal age-related changes and pathological cancer progression. He further articulated a hopeful vision for the future: "As we start to piece together the picture of the most important mutations which evolve during the ageing process in cells from the bone marrow, and the impact they have in disease, we hope we can start to identify opportunities for intervention and maybe even prevention of some age-related cancers." Professor Swanton’s perspective points towards a paradigm shift, where understanding the ageing process itself becomes a key strategy in cancer prevention and treatment.
Implications for Clinical Practice
The implications of this research for clinical practice are substantial and multifaceted. Currently, cancer prognosis and treatment decisions are primarily based on tumour characteristics (stage, grade, molecular markers) and patient-specific factors (age, comorbidities). The discovery of TI-CH introduces a powerful new prognosticator. Clinicians may soon consider screening cancer patients for CHIP mutations in their blood, and potentially for TI-CH within tumour biopsies, to better stratify patient risk. Identifying patients with TI-CH could lead to more aggressive treatment strategies, closer monitoring for relapse, or enrollment in clinical trials for novel therapies specifically designed to counteract the pro-tumourigenic effects of these mutant myeloid cells. For instance, therapies targeting the specific pathways influenced by TET2 mutations, or strategies to modulate the function of myeloid cells within the tumour microenvironment, could emerge as personalized treatment options for this high-risk patient subgroup.
The Broader Scientific Community
This interdisciplinary discovery serves as a powerful testament to the value of collaborative research, bridging insights from gerontology (the study of ageing), haematology (the study of blood), and oncology (the study of cancer). It compels the scientific community to re-evaluate the simplistic view of cancer as solely a disease of rogue cells within a specific organ. Instead, it frames cancer as a systemic disease, deeply intertwined with the host’s overall biological state, particularly the ageing process. This integration of ageing biology into cancer research will undoubtedly stimulate new avenues of inquiry, fostering a more holistic understanding of disease development and progression.
Future Implications and Outlook: Towards a New Era of Cancer Prevention
Mapping the Road Ahead: Unanswered Questions
While this study marks a pivotal advancement, the researchers are clear that it also opens up a new frontier of questions. The immediate next steps involve further confirming that CHIP directly contributes to cancer outcomes, moving beyond strong association to definitive causation. This will require sophisticated experimental models and long-term longitudinal studies. Furthermore, detailing the exact mechanisms by which CHIP is functionally implicated in the development of aggressive cancers remains a critical area of focus. How do TET2 mutant myeloid cells precisely remodel the TME? What specific molecular signals do they release? How do they interact with other immune cells and cancer cells to accelerate growth and metastasis? Answering these questions could unlock specific therapeutic targets.
Beyond these immediate steps, several intriguing research directions emerge. Can the progression of CHIP itself be reversed or mitigated through lifestyle interventions or pharmacological agents, thereby reducing the risk of TI-CH and aggressive cancer? Are there specific drug targets that can effectively neutralize the pro-tumourigenic activity of TET2 mutant myeloid cells without compromising essential immune functions? Could routine CHIP screening become a standard practice for older individuals or those with a high risk of developing certain cancers, allowing for early intervention? The potential impact on immunotherapy, a cornerstone of modern cancer treatment, also warrants investigation; could TI-CH affect the efficacy of checkpoint inhibitors or other immune-modulating drugs?
Towards Preventative Therapies
Ultimately, the long-term vision of this research aligns perfectly with the growing emphasis on preventative therapies. If CHIP, an age-related phenomenon, can be identified and potentially managed before it contributes to aggressive cancer, it represents a monumental leap in disease prevention. By understanding the vulnerabilities introduced by the ageing process, scientists can work towards developing interventions that not only treat established cancers but also prevent their most aggressive forms from ever emerging. This could involve therapies aimed at reducing chronic inflammation, modulating the immune system to favor anti-tumour responses, or even targeting the survival and expansion of specific mutant blood cell clones.
A New Era in Cancer Research
This groundbreaking research, supported by vital funding from Cancer Research UK, the National Institute of Health and Care Research UCLH Biomedical Research Centre, and other key funders, heralds a new era in cancer research. It underscores the profound interconnectedness of biological processes and highlights the potential for interdisciplinary collaboration to unravel complex disease mechanisms. By recognizing the silent threat posed by age-related blood mutations, the scientific community is now better equipped to develop more precise prognostic tools and, crucially, to design innovative strategies for the prevention and treatment of aggressive cancers, offering renewed hope for patients worldwide.
About the Author
